

Xin Chen, CMD, Ph.D.



Dr. Xin Chen is a Distinguished Professor of Biomedical Sciences and the Director of the Institute of Chinese Medical Sciences at the University of Macau. Dr. Chen received his Bachelor and Master of Medicine degrees from Hubei University of Chinese Medicine in 1984 and 1987. He earned his Doctor of Medicine degree from Guangzhou University of Chinese Medicine in 1991 and Doctorate Degree in Medical Science (Immunology) from Radboud University Nijmegen (Netherlands) in 2023. Dr. Chen started his postdoctoral training at the School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK. In April of 1999, he joined the Laboratory of Molecular Immunoregulation, directed by Dr. Joost J Oppenheim at National Cancer Institute (NCI)-Frederick, NIH, USA, as a Visiting Fellow. In 2001, Dr. Chen became a

Scientist II in the Basic Science Program, SAIC-Frederick, Inc., NCI-Frederick. From 2011 to 2014, he was a Senior Scientist in the Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, NCI-Frederick. In October 2014, he joined the University of Macau as a Full Professor.

Dr. Chen's research focuses on immunopharmacology of Chinese Medicine/natural products and biology of regulatory T cells (Tregs). His study has greatly advanced the understanding of the efficacy and mechanism of Chinese medicine and naturally occurring compounds in the regulation of immune function. Together with Dr. Joost J Oppenheim, he for the first time found and reported that TNF through TNFR2 plays a decisive role in the activation, expansion, phenotypic stability and in vivo function of Tregs. His work also led to the discovery that TNFR2 expression represented the most functional suppressive Treg cells including those present in the tumor microenvironment. Furthermore, his group was the first to report that in vivo administration of TNFR2-targeting pharmaceutical agent induced the regression of tumor, through triggering anti-tumor immune responses, in mouse tumor models.

Dr. Chen began serving the Journal of Leukocyte Biology (JLB) as an editorial board member in 2017. Since 2019, he has been a Deputy Editor of JLB.